托法替布单药与联合甲氨蝶呤或阿达木单抗联合甲氨蝶呤治疗类风湿关节炎的患者报告结局:一项IIIB/IV期试验
ORAL Strategy(NCT02187055)是一项IIIB/IV期头对头随机对照试验,在甲氨蝶呤应答不佳的类风湿关节炎患者中比较托法替布5 mg每日两次单药、托法替布5 mg每日两次联合甲氨蝶呤与阿达木单抗40 mg隔周联合甲氨蝶呤。结果显示所有治疗组患者报告结局均较基线大幅改善,多数达到或超过最小临床重要差异;联合治疗相比托法替布单药改善幅度常更大,但组间差异较小。
要点
- 所有治疗组患者报告结局均较基线大幅改善,多数达到或超过最小临床重要差异。
- 第6个月时,托法替布联合甲氨蝶呤相比托法替布单药在PtGA、疼痛和SF-36躯体成分总结评分上改善显著更大。
- 联合治疗相比托法替布单药的改善在其他时间点常更大但不一致,组间差异较小限制临床意义解读。
核心结论
- 托法替布联合甲氨蝶呤、阿达木单抗联合甲氨蝶呤及托法替布单药均使甲氨蝶呤应答不佳的类风湿关节炎患者患者报告结局获得有临床意义的改善。
- 联合治疗相比托法替布单药的改善相对更大,但组间差异较小,限制了对其临床意义的判断。
研究设计与样本
- ORAL Strategy(NCT02187055)为IIIB/IV期头对头随机对照试验,评估托法替布5 mg每日两次单药、托法替布5 mg每日两次联合甲氨蝶呤与阿达木单抗40 mg隔周联合甲氨蝶呤的非劣效性。
- 研究人群为对甲氨蝶呤应答不佳的类风湿关节炎患者。
主要发现
- 所有治疗组患者报告结局均较基线大幅改善,多数达到或超过最小临床重要差异。
- 第6个月时,托法替布联合甲氨蝶呤相比托法替布单药在PtGA、疼痛和SF-36躯体成分总结评分上改善显著更大。
- 联合治疗相比托法替布单药的改善在其他时间点常更大但不一致。
关键数值与推荐
- 评估的患者报告结局包括PtGA、疼痛、HAQ-DI、FACIT-F及SF-36总结与领域评分。
- 主要比较为托法替布5 mg每日两次单药、托法替布5 mg每日两次联合甲氨蝶呤与阿达木单抗40 mg隔周联合甲氨蝶呤。
临床怎么用
- 对于甲氨蝶呤应答不佳的类风湿关节炎患者,托法替布单药或联合甲氨蝶呤均可考虑用于改善患者报告结局。
- 联合治疗在患者报告结局的部分指标上可能优于托法替布单药,但差异较小,临床决策需综合考量。
局限性
- 联合治疗与托法替布单药之间的差异较小,限制了对其临床意义的判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR). METHODS: ORAL Strategy (NCT02187055), a phase IIIB/IV, head-to-head, randomised controlled trial, assessed non-inferiority between tofacitinib 5 mg two times per day monotherapy, tofacitinib 5 mg two times per day+MTX and ADA 40 mg every other week+MTX. PROs assessed included the following: Patient Global Assessment of disease activity (PtGA), Pain, Health Assessment Questionnaire-Disability Index, Functional Assessment of Chronic Illness Therapy-Fatigue and 36-Item Short-Form Health Survey (SF-36) summary and domain scores. RESULTS: Substantial improvements from baseline were reported across all PROs in all treatment arms, which, in the majority, met or exceeded minimum clinically important differences. Compared with tofacitinib monotherapy, tofacitinib+MTX combination treatment conferred significantly greater improvements in PtGA, Pain and SF-36 physical component summary scores at month 6. Statistically or numerically greater improvements were often, but not uniformly, reported for combination treatments compared with tofacitinib monotherapy at other time points. CONCLUSION: Treatment with tofacitinib+MTX, ADA+MTX and tofacitinib monotherapy resulted in clinically meaningful improvements in PROs in MTX-IR patients with RA. These were comparatively greater with combination treatments versus tofacitinib monotherapy, although differences between treatment arms were small, limiting our ability to confer clinical meaning. TRIAL REGISTRATION NUMBER: NCT02187055.
引用
- Strand V, Mysler E, Moots RJ, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019. PMID: 31673419. doi:10.1136/rmdopen-2019-001040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。